[Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] Actually no. CVD would be a contraindication in those patients. With COVID19 almost half the patients have CVD and 60% have clinical injury. So you are applying a drug to a population that otherwise would be excluded.